Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

doi:10.3748/wjg.v26.i41.6455

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6876)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-7) series.

Item

Count

PDF

348

WORD

196

HTML

3493

Figures (1-2)

299

Tables (1-7)

202

Sum=4538

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

601

Download

1737

Sum=2338

Nov 7, 2020 (publication date) through Sep 4, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Nov 7, 2020; 26(41): 6455-6474
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455

Table 2 Unadjusted comparisons of the measured clinical outcomes, health resources utilization, and direct medical costs associated with infliximab maintenance therapy and conventional maintenance therapy during 1-year observation time

	IMT, n = 295			CMT, n = 130			P value
Outcome measure	Mean/%	SD	Median	Mean/%	SD	Median
Clinical outcomes
Surgery rate	12.7%			25.4%			0.002^b
Disease remission rate	94.6%			86.9%			0.008^b
Utility for quality of life	0.890	0.080	0.900	0.757	0.093	0.748	< 0.001
Newly developed complications
Any complications	27.0%			42.3%			0.002^b
Anus fistula	17.4%			14.6%			0.489
Intestinal fistula	3.5%			4.6%			0.582
Intestinal obstruction	4.2%			12.3%			0.003^b
Perianal abscess	5.8%			6.2%			0.886
Bowel perforation	1.9%			3.8%			0.260
Health resource utilization
Outpatient clinic visits	1.9	3.3	1.0	3.7	5.2	2.0	< 0.001
Hospital admissions	5.3	2.2	6.0	1.4	1.0	1.0	< 0.001
Hospital admissions for infliximab administration	4.4	2.2	5.0	0.0	0.0	0.0	< 0.001
Hospital admissions for active disease management	0.9	1.0	1.0	1.4	1.0	1.0	< 0.001
Hospital stay days	15.2	11.1	14.0	14.8	12.4	9.5	0.207
Hospital stay days related to infliximab administration	5.7	3.8	6.0	0.0	0.0	0.0	< 0.001
Hospital stay days for active disease management	9.5	11.3	9.0	14.8	12.4	9.5	< 0.001
Direct medical costs for outpatient clinic visits
Outpatient costs for drugs	¥710	¥4,268	¥0	¥2,342	¥4698	¥644	< 0.001
Outpatient costs for others	¥232	¥589	¥0	¥130	¥446	¥0	0.008^b
Total outpatient costs	¥942	¥4371	¥54	¥2473	¥4777	¥810	< 0.001
Direct medical costs for hospitalizations
Hospital costs related to infliximab administration	¥5,305	¥7650	¥3577	¥0	¥0	¥0	< 0.001
Drug acquisition costs of infliximab	¥39018	¥9610	¥39200	¥0	¥0	¥0	< 0.001
Hospital costs for active disease management	¥11041	¥17982	¥4090	¥24274	¥29285	¥9321	< 0.001
Total hospital costs	¥55365	¥22337	¥52155	¥24274	¥29285	¥9321	< 0.001
Total direct medical costs	¥56307	¥23866	¥52476	¥26747	¥30541	¥12503	< 0.001

^bP < 0.01. CMT: Conventional maintenance therapy; IMT: Infliximab maintenance therapy; SD: Standard deviation.

Citation: Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474
URL: https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i41.6455